Biologics CMC Series (2): ICH Q6B Biologics Specifications: A Complete Guide to CQAs, Analytical Methods, and Release Criteria

ICH Q6B Biologics Specifications: A Specification Is More Than a Testing Checklist

When scientists first encounter biologics CMC, it is easy to think of a specification as a table: the test appears in the first column, the analytical method in the second, and the acceptance criterion in the third.

For example:

• Appearance: clear to slightly opalescent

• Protein concentration: within a defined range

• Purity: not less than a specified percentage

• Potency: within an approved range

On the surface, that is a specification.

The difficult part, however, is not completing the table. It is answering three questions:

1. Why must this quality attribute be included in the specification?

2. Why is this analytical procedure appropriate for controlling it?

3. Why does this acceptance criterion adequately protect product safety and efficacy?

The value of ICH Q6B is that it provides a shared framework for development, analytical, QC, QA, CMC, manufacturing, and regulatory teams to answer those questions.

As of 2026, the current ICH Q6B guideline remains the version finalized in 1999. It primarily applies to proteins, polypeptides, and their derivatives produced through recombinant or non-recombinant cell-culture expression systems that can be highly purified and well characterized. ICH has initiated the revision of Q6A and Q6B, but the emerging Q6(R1) direction should not be presented as an implemented requirement until the revision is finalized and adopted in the relevant regions.

Executive Summary

• A specification is a combination of tests, analytical procedures, and acceptance criteria. It is not the complete product-characterization package.

• The central Q6B categories include identity, purity and impurities, potency, quantity, and product-appropriate general tests.

• Not every critical quality attribute must become a routine release test. Some attributes may be controlled through raw-material controls, process parameters, in-process controls, or characterization.

• Acceptance criteria should not be established solely by calculating the mean plus or minus three standard deviations from a few batches. Clinical experience, process capability, analytical variability, stability, and safety relevance must also be considered.

• Drug substance and drug product specifications should reflect their different risks rather than duplicate the same testing panel.

• Q6B should be used together with ICH Q2(R2), Q5C, Q5E, Q8, Q9, Q10, Q11, Q12, Q14, and CTD Module 3.

• The Q6(R1) revision is expected to place greater emphasis on clinically relevant specifications, prior knowledge, science- and risk-based approaches, and modalities such as cell and gene therapies, vaccines, oligonucleotides, and antibody-drug conjugates.

A Plain-Language Introduction: What Is a Biologics Specification?

Imagine a biologic as a complex paper airplane manufactured by living cells.

We cannot reasonably confirm that every atom in every molecule is identical. Instead, we identify the characteristics that determine whether the airplane can fly as intended—for example, its weight, wing angle, symmetry, and material strength—and define acceptable ranges for those characteristics.

A biologics specification serves a similar purpose.

It does not require every batch to produce identical numbers for every measured attribute. It defines a scientifically justified quality space within which there is reasonable confidence that the product retains its intended identity, strength, quality, purity, and potency.

This is also why a specification cannot simply be copied from another biologic. Two monoclonal antibodies may appear similar, yet differ in mechanism of action, dose, route of administration, manufacturing process, formulation, and major degradation pathways. Their control strategies and acceptance criteria therefore need to reflect product-specific risks.

What Does ICH Q6B Actually Cover?

ICH Q6B defines a specification as the combination of three elements:

1. A list of tests

2. References to the corresponding analytical procedures

3. Appropriate acceptance criteria, including numerical limits, ranges, or other criteria

Its purpose is to establish harmonized principles for specifications for biotechnological and biological products used in marketing applications across ICH regions.

Importantly, Q6B does not require every analytical method used during development to become part of routine release testing.

During development, teams may use peptide mapping, multiple orthogonal chromatographic methods, mass spectrometry, glycan profiling, biophysical analysis, higher-order structure studies, and several functional assays to establish a deep understanding of the product. A commercial release specification generally selects a smaller group of robust, discriminating, and operationally sustainable methods that control the most important quality risks.

Characterization, CQAs, and Specifications: What Is the Difference?

Characterization: Building Deep Product Knowledge

Characterization establishes the structural and functional fingerprint of a product. It is generally broader and deeper than routine specification testing and may use specialized or lower-throughput technologies.

For a monoclonal antibody, characterization may include:

• Primary amino acid sequence and molecular mass

• Disulfide-bond mapping

• Glycan profile

• Charge variants

• Size variants

• Higher-order structure

• Antigen binding

• Fc-receptor binding

• Cell-based biological activity

Together, these data help a development team understand what the product is and which forms of variation could create meaningful risk.

Critical Quality Attributes: Which Attributes Could Affect the Patient?

A critical quality attribute, or CQA, is a physical, chemical, biological, or microbiological property that should remain within an appropriate limit, range, or distribution to ensure product quality.

Whether an attribute is considered critical generally depends on its potential effect on safety, efficacy, immunogenicity, pharmacokinetics, or manufacturability, as well as the uncertainty surrounding that effect.

Aggregation, for example, may affect potency, exposure, and immunogenicity and is therefore often treated as an important CQA. Whether a specific glycan species should be treated as a CQA depends on its potential effect on Fc-mediated function, clearance, or safety.

Specifications: Which Attributes Require a Batch Decision at a Defined Control Point?

A specification is one component of the control strategy. It is commonly used to determine whether a drug-substance or drug-product batch can be released and whether the product remains acceptable through the end of shelf life.

The three concepts therefore serve different purposes:

• Characterization builds knowledge.

• CQAs connect product attributes to patient and product risk.

• Specifications support quality decisions at selected control points.

A CQA does not automatically need to become a final release test. If a team has strong process understanding and can control an attribute reliably through raw-material controls, validated process parameters, in-process controls, or another upstream control, regulators may accept an approach that does not test the attribute in every final batch. That position requires a coherent evidence package; a statement that “the process is consistent” is not sufficient.

Core Test Categories in ICH Q6B Biologics Specifications

Identity: Confirming That the Correct Product Is Present

An identity test should distinguish the intended product from other potentially confounding products or substances.

Possible approaches include peptide mapping, an immunochemical assay, a characteristic chromatographic profile, or another sufficiently specific procedure. In practice, a nonspecific total-protein measurement alone is unlikely to provide adequate identity assurance.

Purity and Impurities: More Than a Single Purity Percentage

Impurities associated with biologics are generally divided into two major categories:

• Product-related impurities arise from changes to or degradation of the product itself. Examples include aggregates, fragments, oxidized variants, deamidated variants, and undesirable charge variants.

• Process-related impurities arise from manufacturing. Examples include host-cell proteins, residual host-cell DNA, residual Protein A, media components, antibiotics, or other process residues.

Teams must also consider contaminants, including microorganisms, viruses, endotoxin, and adventitious agents.

A common mistake is to use one SEC purity result as a proxy for total purity. SEC can measure size variants, but it cannot replace the control of charge heterogeneity, chemical modifications, host-cell proteins, residual DNA, or other relevant risks.

Potency: Connecting Molecular Quality to Biological Function

Potency is one of the most important—and often most difficult—components of a biologics specification.

Q6B connects potency with the biological activity of the product. Appropriate analytical strategies may include:

• A cell-based bioassay

• A binding assay

• An enzymatic activity assay

• A matrix of complementary assays

The appropriate method depends on the mechanism of action. If the clinical function of a product depends on receptor activation, cell killing, or a multistep signaling pathway, a simple binding assay may not adequately represent biological activity.

Cell-based assays, however, often have greater variability. The acceptance range should account for assay variability, but it should not be widened so far that the assay loses its ability to discriminate meaningful change. The better solution is usually to improve the method, reference-standard strategy, system suitability, and statistical model.

Quantity: Confirming the Amount of Active Ingredient

Quantity may be reported as protein concentration, mass, biological units, or another suitable measure. It is related to potency, but the two are not interchangeable.

A sample may contain the expected protein concentration while having reduced potency because of structural change or loss of activity. Quantity therefore cannot replace functional testing.

General Tests: Selected According to Dosage Form and Product Risk

Common general tests may include:

• Appearance, color, and clarity

• pH

• Osmolality

• Particulate matter

• Sterility

• Bacterial endotoxins

• Bioburden at applicable manufacturing stages

• Controls associated with container-closure integrity

Not all of these requirements originate directly from Q6B. Some derive from pharmacopeial chapters, requirements for sterile products, product-specific guidance, or regional regulations. An effective specification integrates these sources into one product-specific control strategy.

Why Drug Substance and Drug Product Specifications Should Not Be Identical

Drug substance and drug product face different risks.

A drug-substance specification often places greater emphasis on the molecule and on risks originating in upstream and downstream processing, including identity, purity, aggregates, charge variants, potency, host-cell proteins, residual DNA, residual Protein A, and bioburden.

After formulation, filtration, filling, container closure, and storage, the drug product may require additional controls for:

• Fill volume or extractable volume

• Protein concentration or delivered dose

• Visible and subvisible particles

• Sterility and endotoxin

• pH and osmolality

• Container-closure interactions

• Shelf-life degradation

• In-use stability, when applicable

Some attributes may appear in both specifications, but their acceptance criteria may differ. For example, the aggregate limit for drug product must account for filling and long-term storage throughout shelf life. The drug-substance release limit may need to be tighter to allow for changes during subsequent manufacturing and storage.

How Should Acceptance Criteria Be Established?

One of the most common—and most problematic—approaches is to calculate the mean plus or minus three standard deviations from a small number of early-development batches and treat the resulting interval as the final commercial specification.

Statistics help describe a process, but a regulatory acceptance criterion is not merely a statistical description of manufacturing performance. It must also protect the patient.

A more complete justification generally integrates:

1. Clinical experience: What quality ranges were represented by the batches administered in clinical studies?

2. Safety and efficacy relevance: Could a change in the attribute affect efficacy, safety, pharmacokinetics, or immunogenicity?

3. Manufacturing history: What is the demonstrated process capability, and do the data include commercial-scale or process-performance-qualification batches?

4. Analytical variability: What are the precision and measurement uncertainty of the analytical procedure?

5. Stability data: Will the release limit ensure that the product remains within specification through the end of shelf life?

6. Platform and prior knowledge: What credible knowledge can be applied from the same molecule class, process, or analytical platform?

7. Reference standards: How are results controlled through qualified standards and system-suitability criteria?

Ideally, an acceptance criterion should be more conservative than a boundary known to affect clinical performance, while still reflecting a controlled and sufficiently capable manufacturing process.

If clinical batches occupied a narrow quality range but the proposed commercial specification is much wider, reviewers are likely to ask whether patients were ever exposed to the proposed range and what evidence supports safety and efficacy outside the clinical experience.

A Simplified Monoclonal Antibody Specification Example

Consider an IgG monoclonal antibody whose primary mechanism of action is receptor blocking.

A possible drug-substance release-specification framework is shown below. This is an educational example, not a regulatory template. Every test and numerical limit must be justified using product-specific evidence.

Test	Purpose	Possible Method	Central Development Question
Identity	Confirm molecular identity	Peptide mapping or immunoassay	Can the method distinguish the product from closely related materials?
Protein concentration	Control quantity	UV absorbance	Are the extinction coefficient and method variability understood?
Size variants	Control aggregates and fragments	SEC-HPLC	Which species could affect safety or potency?
Charge variants	Monitor heterogeneity	icIEF or CEX	Is routine batch testing needed, or can characterization and process controls manage the risk?
Purity and fragments	Provide complementary purity information	CE-SDS	What do reducing and nonreducing conditions each reveal?
Potency	Confirm biological activity	Cell-based or binding assay	Is the method sufficiently connected to the primary mechanism of action?
Host-cell proteins	Control process-related impurities	ELISA	Have assay coverage and product interference been evaluated?
Residual DNA	Control process-related impurities	qPCR	Are sampling, recovery, and fragment-size risks understood?
Endotoxin	Protect patient safety	Compendial method	Is the limit based on dose and route of administration?
Bioburden	Support subsequent sterile processing	Compendial method	Are the sampling point and hold time appropriate?

The real work is not placing this table in a submission. It is building the evidence chain behind every row.

Where Do Specifications Appear in CTD Module 3?

Under the current M4Q(R1) structure, common locations include:

• 3.2.S.4.1: Drug Substance Specification

• 3.2.S.4.2: Analytical Procedures

• 3.2.S.4.3: Validation of Analytical Procedures

• 3.2.S.4.4: Batch Analyses

• 3.2.S.4.5: Justification of Specification

• 3.2.P.5.1–3.2.P.5.6: Corresponding drug-product information

This structure highlights an important point: the specification table, analytical methods, validation, batch data, and justification are five connected but noninterchangeable parts of the quality package.

Consistent batch-analysis results do not, by themselves, demonstrate that a limit is clinically meaningful. Likewise, a validated method is not automatically capable of detecting changes that matter to product function.

As of 2026, ICH M4Q(R2) remains under development. Its direction is to use Module 2.3 to present overall development, the overall control strategy, core quality information, and lifecycle management more clearly, while Module 3 retains detailed methods, data, and supporting information. Companies can begin organizing knowledge according to this integrated logic, but formal submissions must continue to follow versions implemented in the relevant regions and any applicable regional requirements.

Which Guidelines Should Be Read Together With Q6B?

ICH Q2(R2) and Q14: Demonstrating That a Method Is Fit for Purpose

Q6B helps define what needs to be controlled. Q14 and Q2(R2) address analytical procedure development and validation, respectively.

A method can have a technically polished validation report and still be inadequate for a specification if its analytical target profile is unclear or it lacks sensitivity to relevant variants.

ICH Q5C: Connecting Release and Shelf-Life Specifications

Biologics can be sensitive to temperature, oxidation, light, agitation, and freeze-thaw stress. Stability-indicating methods should detect storage-related change, and release limits should account for expected drift through shelf life.

ICH Q5E: Passing Specifications Does Not Establish Comparability

When a process, scale, manufacturing site, or equipment train changes, demonstrating that pre-change and post-change batches both pass their specifications only shows that each batch falls within its respective approved limits. It does not, by itself, establish that the products are highly similar.

Comparability generally requires broader characterization, side-by-side analysis, and a risk-based assessment. This will be the central topic of the next article in this series.

ICH Q8, Q9, Q10, and Q11: Specifications Are the Final Safety Net, Not the Entire Control Strategy

A mature control strategy does not transfer every risk to final-product testing. It connects material attributes, process parameters, in-process controls, release tests, the stability program, and the pharmaceutical quality system.

If the process is not understood, final release testing alone cannot provide reliable assurance of consistent product quality.

Six Common Practical Mistakes

1. Moving the full characterization panel into routine specifications, creating a complex and expensive QC system without materially improving patient protection.

2. Establishing final commercial limits using only a few engineering or early clinical batches.

3. Using a potency assay with weak relevance to the mechanism of action simply because a binding assay is easier to operate.

4. Treating analytical method validation and method suitability as the same concept.

5. Using identical drug-substance and drug-product specifications without accounting for formulation, filling, container closure, and shelf-life risks.

6. Claiming comparability because batches pass specifications while overlooking the broader analytical assessment expected under Q5E.

Where Is Q6B(R1) Expected to Take Biologics Specifications?

ICH endorsed the concept for revising Q6A and Q6B in 2024. This does not mean the revised guideline is already effective, but it clearly signals the direction of regulatory science.

Expected areas of emphasis include:

• Greater alignment of common principles across Q6A and Q6B

• Positioning specifications within the overall control strategy rather than as an isolated table of tests

• More explicit use of prior knowledge and science- and risk-based approaches

• Greater emphasis on clinically relevant justification in addition to historical batch data

• Expanded coverage of products that were not adequately addressed by the original guidelines, including cell and gene therapies, vaccines, oligonucleotides, antibody-drug conjugates, and certain combination products

• Incorporation of advances in analytical technologies, manufacturing science, predictive modeling, and statistical approaches

The best preparation is not to wait for the revised guideline. Development teams can begin now by strengthening the evidence chain that explains how each test and limit protects the patient.

Practical Q6B Capabilities That Development Teams Need

Reading the guideline is only the starting point. Practical capabilities include:

• Establishing traceability among the quality target product profile, CQAs, and specifications

• Distinguishing characterization, release, stability, and comparability methods

• Using clinical batches, process capability, and stability data to justify acceptance criteria

• Determining which CQAs can be managed through process controls and which require routine batch testing

• Designing a potency strategy that reflects the mechanism of action

• Writing the justification of specifications for CTD sections 3.2.S.4.5 and 3.2.P.5.6

• Progressively refining specifications from early clinical development to commercialization rather than freezing immature limits too early

• Assessing whether a new analytical method or manufacturing change requires comparability, bridging, or regulatory reporting

Conclusion: A Strong Specification Is a Traceable Scientific Argument

The most valuable lesson in ICH Q6B is not a fixed list of tests. It is a way of thinking.

A mature biologics specification should be traceable from patient risk to CQAs and from those CQAs to analytical methods, process controls, and acceptance criteria. Every test should have a reason to exist. Every limit should be supported by evidence. Every attribute excluded from routine testing should be controlled elsewhere in the strategy.

When that evidence chain is complete, an ICH Q6B biologics specification becomes more than a release table. It becomes the most concise expression of the overall control strategy.

The next article in this series will examine ICH Q5E comparability and a challenge that nearly every biologics team eventually encounters: after changing the process, how can we demonstrate that the product remains comparable?

LuTra Studio: Turning Complex CMC Questions Into Actionable Strategy

Biologics specification design often requires analytical development, process development, QC, QA, clinical, regulatory affairs, and manufacturing teams to work from the same scientific narrative. The hardest part is rarely locating a guideline. It is integrating cross-functional evidence into a coherent strategy that can support both development decisions and regulatory submissions.

LuTra Studio provides consulting support in biotechnology strategy, CMC, and cross-functional scientific communication. We help teams clarify control strategies, technical narratives, development risks, and program priorities. If your organization is moving from early development toward an IND, BLA, technology transfer, or commercial readiness, you can contact LuTra Studio to discuss how these elements can be connected into an executable plan.

References

1. ICH. Q6B: Specifications—Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999. https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf

2. FDA. Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. August 1999. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6b-specifications-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products

3. EMA. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products-scientific-guideline

4. ICH. M4Q(R1): The Common Technical Document for the Registration of Pharmaceuticals for Human Use—Quality. https://database.ich.org/sites/default/files/M4Q_R1_Guideline.pdf

5. ICH. Final Concept Paper: Maintenance of the ICH Q6A and Q6B Guidelines (Q6(R1)); endorsed July 18, 2024. https://database.ich.org/sites/default/files/ICH_Q6%28R1%29_Final_ConceptPaper_2024_0625.pdf

6. ICH. M4Q(R2) Draft Guideline and Step 2 Supporting Materials. 2025–2026. https://www.ich.org/page/ctd

7. FDA. Analytical Procedures and Methods Validation for Drugs and Biologics. 2015. https://www.fda.gov/files/drugs/published/Analytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf

8. EMA. ICH Guidelines: Quality. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/ich-guidelines/ich-guidelines-quality